This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Approaches to disease modification in MS

Authoring team

The following therapeutic strategies are accepted or are under investigation:

  • non-specific immune suppression

  • inhibition of interaction between T cell and antigen presenting cell

  • interuption of lymphocyte migration into the central nervous system

  • alteration of the balance of immune activation away from pro-inflammatory Th1 lymphocytes

  • promotion of remyelination

In practise only beta-interferon has been shown to alter the activity of the disease and possibly to reduce disability. Intravenous immunoglobulin and glatitramer acetate are promising alternatives.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.